Corvus Pharmaceuticals (NASDAQ:CRVS) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS

Corvus Pharmaceuticals (NASDAQ:CRVS) posted its quarterly earnings data on Tuesday. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.06), Zacks reports.

Corvus Pharmaceuticals Price Performance

Shares of CRVS stock traded down $0.32 during trading on Tuesday, reaching $3.93. The company’s stock had a trading volume of 1,041,060 shares, compared to its average volume of 564,653. Corvus Pharmaceuticals has a 1-year low of $1.30 and a 1-year high of $10.00. The stock’s 50-day moving average price is $4.72 and its 200 day moving average price is $6.10. The company has a market capitalization of $252.53 million, a price-to-earnings ratio of -4.23 and a beta of 0.91.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $11.00 price target on shares of Corvus Pharmaceuticals in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Corvus Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $12.38.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.